WELCOME TO ACTELION S AGM 2015

Size: px
Start display at page:

Download "WELCOME TO ACTELION S AGM 2015"

Transcription

1 WELCOME TO ACTELION S AGM May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd

2 ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre Garnier, Chairman of the Board Jean-Paul Clozel, Chief Executive Officer André Muller, Chief Financial Officer Jean-Pierre Garnier, Chairman of the Board Marian Borovsky, Secretary of the Board of Directors Actelion Pharmaceuticals Ltd 08 May 2015

3 FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING Actelion Pharmaceuticals Ltd 08 May 2015

4 IHR epad / YOUR epad Ja Oui Yes Enthaltung Abstention Abstention Nein Non No Actelion Pharmaceuticals Ltd 08 May 2015

5 FORMAL DECLARATIONS REGARDING THE CONSTITUTION OF THE MEETING Actelion Pharmaceuticals Ltd 08 May 2015

6 OPENING REMARKS BY THE CHAIRMAN OF THE BOARD Jean-Pierre Garnier Actelion Pharmaceuticals Ltd 08 May 2015

7 ACTELION SHARE PRICE PERFORMANCE Selexipag results Share price development +53% in 2014 SNB announcement AGM 2014 ACTELION SWISS SMI Jan-14 Apr-14 Jul-14 Oct-14 Jan-15 Apr Actelion Pharmaceuticals Ltd 08 May 2015

8 DELIVERING ON OUR STRATEGY CREATES VALUE > CHF 1 BILLION RETURNED TO SHAREHOLDERS OVER 3 YEARS SHARE PRICE PERFORMANCE DIVIDEND PAYMENT Actelion Pharmaceuticals Ltd 08 May 2015

9 CONTINUED CASH RETURNED TO SHAREHOLDERS 2015 INITIATIVES New second-line share repurchase: up to 10 million shares within 3 years Increased dividend: Board proposal CHF 1.30 per share Actelion Pharmaceuticals Ltd 08 May 2015

10 OPENING REMARKS BY THE CHAIRMAN OF THE BOARD Jean-Pierre Garnier Actelion Pharmaceuticals Ltd 08 May 2015

11 OUTSTANDING PERFORMANCE IN 2014 Jean-Paul Clozel, CEO Actelion Pharmaceuticals Ltd 08 May 2015

12 OUR STRATEGIC PRIORITIES STAY THE SAME ACHIEVEMENTS 2014: WE ARE ON TRACK SUSTAIN AND GROW THE PAH FRANCHISE BUILD ADDITIONAL SPECIALTY FRANCHISES OPTIMIZE PROFITABILITY Actelion Pharmaceuticals Ltd 08 May 2015

13 OUR STRATEGIC PRIORITIES STAY THE SAME ACHIEVEMENTS 2014: WE ARE ON TRACK SUSTAIN AND GROW THE PAH FRANCHISE BUILD ADDITIONAL SPECIALTY FRANCHISES OPTIMIZE PROFITABILITY Actelion Pharmaceuticals Ltd 08 May 2015

14 OPSUMIT ENGINE OF TRANSFORMATION Opsumit (macitentan) is an orally available endothelin receptor antagonist (ERA) approved for the treatment of PAH in over 30 countries, including the United States in October 2013 and the European Union in December Actelion Pharmaceuticals Ltd 08 May 2015

15 OPEN THE PROSTACYCLIN PATHWAY TO MORE PATIENTS Selexipag (Uptravi) is an investigational drug submitted to health authorities but not approved for use Actelion Pharmaceuticals Ltd 08 May 2015

16 UNIQUELY POSITIONED TO SERVE PAH COVERING CONTINUUM OF CARE WITH OUTCOME-BASED MEDICINES FC II FC III FC IV * Selexipag (Uptravi) is an investigational drug submitted to health authorities but not approved for use Actelion Pharmaceuticals Ltd 08 May 2015

17 OUR CARDIOVASCULAR PIPELINE PROMISING PROJECTS TO DELIVER FUTURE SUCCESS Selexipag PAH Macitentan Eisenmenger syndrome Macitentan CTEPH Macitentan CpcPH Selexipag Raynaud s 2 o to SSc New Chemical Entity Cardiovascular disorders Phase I Phase II Phase III Filing Actelion Pharmaceuticals Ltd 08 May 2015

18 OUR STRATEGIC PRIORITIES STAY THE SAME ACHIEVEMENTS 2014: WE ARE ON TRACK SUSTAIN AND GROW THE PAH FRANCHISE BUILD ADDITIONAL SPECIALTY FRANCHISES OPTIMIZE PROFITABILITY Actelion Pharmaceuticals Ltd 08 May 2015

19 SPECIALTY PRODUCT PORTFOLIO Actelion Pharmaceuticals Ltd 08 May 2015

20 OUR SPECIALTY PIPELINE PROMISING PROJECTS TO DELIVER FUTURE SUCCESS Cadazolid Clostridium difficile assoc. diarrhea Ponesimod Multiple Sclerosis Ponesimod Graft vs. host disease S1P 1 modulator Systemic lupus erythematosus Lucerastat Fabry disease Macitentan Glioblastoma New Chemical Entity Neurological disorders Phase I Phase II Phase III Filing Actelion Pharmaceuticals Ltd 08 May 2015

21 OUR STRATEGIC PRIORITIES STAY THE SAME ACHIEVEMENTS 2014: WE ARE ON TRACK SUSTAIN AND GROW THE PAH FRANCHISE BUILD ADDITIONAL SPECIALTY FRANCHISES OPTIMIZE PROFITABILITY Actelion Pharmaceuticals Ltd 08 May 2015

22 OPTIMIZE PROFITABILITY ACHIEVEMENTS 2014 Strong sales performance Good cost control Markedly increased earnings per share Strong balance sheet assuring financial flexibility Total shareholder return of 55% Actelion Pharmaceuticals Ltd 08 May 2015

23 2015 FOCUS ON EXECUTION MAINTAIN successful Opsumit launch momentum OBTAIN regulatory approval for selexipag (Uptravi) INITIATE and ADVANCE key clinical programs DRIVE shareholder value creation Actelion Pharmaceuticals Ltd 08 May 2015

24 STRONG FINANCIAL PERFORMANCE IN 2014 André C. Muller, CFO Actelion Pharmaceuticals Ltd 08 May 2015

25 FULL YEAR 2014 FINANCIAL OVERVIEW Variance FY 2013 FY 2014 CHF CER Product sales CHF million Core earnings CHF million Operating income CHF million Core EPS CHF 1,784 1,956 10% 12% % 25% % 24% % 33% Actelion Pharmaceuticals Ltd 08 May 2015

26 FULL YEAR 2014 PRODUCT SALES PRODUCTS SALES GROWTH OF 12%, INTRINSIC GROWTH OF 10% CHF million ,784 1,956 1,956 FY '13 Sales FY '14 intrinsic sales growth US rebate reversals FX FY'14 Sales Actelion Pharmaceuticals Ltd 08 May 2015

27 FY 2014: STRONG COMMERCIAL PERFORMANCE TRANSITIONING US + CHF 85 million Europe + CHF 66 million Japan + CHF 16 million RoW +CHF 14 million Opsumit + CHF 175 million Tracleer - CHF 43 million Veletri + CHF 28 million Ventavis + CHF 0.2 million Zavesca + CHF 9 million Others + CHF 12 million Total + CHF 181 million Total + CHF 181 million Actelion Pharmaceuticals Ltd 08 May 2015

28 FY 2014 CORE EARNINGS CORE EARNINGS UP 25% AT CER CHF million ,956 1, Product sales Core COS Core R&D Core SG&A 2014 Core earnings Actelion Pharmaceuticals Ltd 08 May 2015

29 FY 2014 NET INCOME CHF million FY'14 Core earnings Non-core items FY '14 Operating Income Financial result Income tax expense One time deferred tax benefits FY '14 Net Income Actelion Pharmaceuticals Ltd 08 May 2015

30 FY 2014 CASH FLOW CHF million ,036 1, ,205 Unrestricted gross cash 31 Dec 13 Operating cash flow (ex litigation) Litigation payment Released restricted cash Dividend 1st line share purchase Proceeds from ESOP Capex, other items Unrestricted gross cash 31 Dec Actelion Pharmaceuticals Ltd 08 May 2015

31 Q FINANCIAL OVERVIEW Variance Q Q CHF CER Product sales CHF million Core earnings CHF million Operating income CHF million Core EPS CHF % 12% % 18% % 28% % 12% Actelion Pharmaceuticals Ltd 08 May 2015

32 2015 FINANCIAL GUIDANCE AT CONSTANT EXCHANGE RATES Core earnings growth low double-digit percentage range (excl US rebate reversals) Actelion Pharmaceuticals Ltd 08 May 2015

33 CONCLUDING REMARKS BY THE CHAIRMAN OF THE BOARD Actelion Pharmaceuticals Ltd 08 May 2015

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

Review of Half Year 2010

Review of Half Year 2010 Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia

Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia Page 1 of 6 Media Release 07 July 2016 Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia Investor webcast to provide background information

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Cowen Healthcare Conference

Cowen Healthcare Conference Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT

More information

Interim report Second quarter 2017 and subsequent events (Unaudited)

Interim report Second quarter 2017 and subsequent events (Unaudited) SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities

More information

Welcome to the Full -Year Results Press Conference

Welcome to the Full -Year Results Press Conference Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Arkadin Managed Calls

Arkadin Managed Calls Arkadin Managed Calls ThromboGenics Conference Call FY 2017 Business Update & Results Thursday 15.03.2018 18u30 CET Speakers: Patrik De Haes, MD, CEO and Dominique Vanfleteren, CFO Call Duration: 19:05

More information

4 th Quarter 2017 Earnings Review & Investor Update

4 th Quarter 2017 Earnings Review & Investor Update 4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking

More information

Third Quarter Results to September 30, 2009

Third Quarter Results to September 30, 2009 Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals

More information

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

Actelion provides an update on the progress towards launching Idorsia Key results for pipeline assets to be developed by Idorsia

Actelion provides an update on the progress towards launching Idorsia Key results for pipeline assets to be developed by Idorsia Page 1 of 7 Media Release 22 May 2017 Actelion provides an update on the progress towards launching Idorsia Key results for pipeline assets to be developed by Idorsia Positive dose-finding results with

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Merrill Lynch Conference Julian Heslop, CFO Sept 17 th 2010

Merrill Lynch Conference Julian Heslop, CFO Sept 17 th 2010 Merrill Lynch Conference Julian Heslop, CFO Sept 17 th 2010 GSK s strategic priorities Grow a diversified global business Deliver more products of value Simplify the operating model Turnover and EPS progression

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007

Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007 Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

NASDAQ: FHCO 2016 Annual Meeting

NASDAQ: FHCO 2016 Annual Meeting NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting

More information

ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST

ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can

More information

Cochlear Limited 2017 Annual General Meeting Chairman s Address

Cochlear Limited 2017 Annual General Meeting Chairman s Address Cochlear Limited 2017 Annual General Meeting Chairman s Address 17 October 2017 Rick Holliday-Smith Chairman Ladies and gentlemen Financial results Cochlear reported a record net profit of $224 million,

More information

First Quarter Results to March 31, Shire plc April 25, 2008

First Quarter Results to March 31, Shire plc April 25, 2008 First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

SG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc

SG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

JP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011

JP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011 JP Morgan 2011 Healthcare Conference David Redfern, Chief Strategy Officer 12 January 2011 GSK performance through patent cliff + Avandia GSK patent cliff + Avandia 2006-2009 US turnover for se elected

More information

Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress

Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress Company Announcement No. 48 / 2015 Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress Lyxumia royalties and milestone

More information

Full Year and Fourth Quarter Results ended 31 December Shire Pharmaceuticals Group plc

Full Year and Fourth Quarter Results ended 31 December Shire Pharmaceuticals Group plc Full Year and Fourth Quarter Results ended 31 December 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

INTERIM MANAGEMENT STATEMENT Q3 2017

INTERIM MANAGEMENT STATEMENT Q3 2017 INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other SELEXIPAG UPTRAVI 42922 TREPROSTINIL ORENITRAM ER 40827 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

Leading Intimate Healthcare

Leading Intimate Healthcare 21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Science, patient benefits and productivity

Science, patient benefits and productivity Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Second Quarter Results to June 30, 2010

Second Quarter Results to June 30, 2010 Second Quarter Results to June 30, 2010 Shire plc August 4, 2010 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals Sylvie

More information

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011 Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009 27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»

More information

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011 H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts

More information

Morgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc

Morgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc Morgan Stanley CEOs Unplugged January 3, 2008 Matthew Emmens, CEO Shire plc Introduction Strategy on track Excellent third quarter results Strong product sales reflecting good results and successful product

More information

2017 Annual General Meeting

2017 Annual General Meeting Cedar Woods Presentation 1 Cedar Woods Properties Limited 2017 Annual General Meeting 9 November 2017 Cedar Woods Presentation 2 Agenda 1 Chairman s Address Mr William G Hames 2 Managing Director s Review

More information

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 (Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

TELECONFERENCE FY February 2015

TELECONFERENCE FY February 2015 TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

Presentation First quarter 2006

Presentation First quarter 2006 Immunity for Life TM Presentation First quarter 2006 CEO Gunnar Rørstad CFO Finn Samuelsen 10 May 2006 Highlights - operations Inclusion of patients almost completed in the the phase II clinical trial

More information

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking

More information

Therapeutic products for respiratory and autoimmune diseases. Annual General Meeting

Therapeutic products for respiratory and autoimmune diseases. Annual General Meeting Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding

More information

Full Year Update FY2011 May 2011

Full Year Update FY2011 May 2011 Full Year Update FY2011 May 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High level

More information

Bank of America Merrill Lynch 2016 Health Care Conference

Bank of America Merrill Lynch 2016 Health Care Conference Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information

More information

Fiscal Year 2003 Consolidated 1 st Quarter Business Performance. Eisai Co., Ltd.

Fiscal Year 2003 Consolidated 1 st Quarter Business Performance. Eisai Co., Ltd. Fiscal Year 2003 Consolidated 1 st Quarter Business Performance Eisai Co., Ltd. 1 Consolidated 1 st Quarter Performance Net Sales A Start According to Plan 2002 st Quarter 1 st 115.2 2003 st Quarter 1

More information

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Leading Intimate Healthcare. Investor presentation Q1 2007/08 Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1

More information

METVIX PDT ON THE MARKET IN GERMANY AND UK

METVIX PDT ON THE MARKET IN GERMANY AND UK METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015 Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking

More information

2013 half-year results. 31 July 2013

2013 half-year results. 31 July 2013 2013 half-year results 31 July 2013 Disclaimer and safe harbour 2 Forward-looking statements: This presentation contains forward-looking statements based on current plans, estimates and beliefs of management.

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q3 18 Earnings Supplemental Slides

Q3 18 Earnings Supplemental Slides (Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

Zealand Pharma A/S Interim report for Q (un-audited)

Zealand Pharma A/S Interim report for Q (un-audited) Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and

More information

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Half Year Update FY2012 November 2011

Half Year Update FY2012 November 2011 Half Year Update FY2012 November 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High

More information

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE

More information

Third Quarter Consolidated Financial Results

Third Quarter Consolidated Financial Results Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2014 1. Overview of consolidated results 2. Highlights of Business Performance 3. Actual and Forecast of Main Subsidiary

More information

Zealand announces full year results in line with guidance and release of its Annual Report for 2015

Zealand announces full year results in line with guidance and release of its Annual Report for 2015 Company announcement No. 5 / 2016 Zealand announces full year results in line with guidance and release of its Annual Report for 2015 2015 was a transitional year for Zealand with considerable business

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

DS-8201 Strategic Collaboration

DS-8201 Strategic Collaboration DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections

More information

Reynolds American to Acquire Lorillard

Reynolds American to Acquire Lorillard Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can

More information